Thema
610
28
Recruitment Status: Recruiting
Study Type: Interventional
26
Phase: Phase 2/Phase 3
6
Medical Condition: COVID-19 disease. COVID-19;U07.2, U07
4
Phase: Phase 2
4
Phase: Phase 4
4
Medical Condition: ;B44.0 - Invasive pulmonary aspergillosis
2
Medical Condition: Anosmia. Anosmia;R43.0
2
Medical Condition: COVID-19 Delta Variant; COVID-19 Delta Variant;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases;Emergency medicine - Other emergency care
2
Medical Condition: COVID-19 pneumonia. COVID-19, virus identified;U07.1
2
Medical Condition: COVID-19. COVID-19, virus identified;U07.1
2
Medical Condition: COVID-19;Type 2 diabetes;Steroid induced hyperglycaemia; COVID-19 Type 2 diabetes Steroid induced hyperglycaemia;Metabolic and Endocrine - Diabetes;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases
2
Medical Condition: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
2
Medical Condition: Novel Coronavirus Pneumonia (COVID-19)
2
Medical Condition: Persistent (>1 month) loss of smell within 3 months of COVID-19 (SARS-CoV-2 infection) diagnosis based on a positive test Infections and Infestations
2
Medical Condition: The eligible COVID-19 patients who admit at Ramathibodi Hospitel, Ramathibodi Hospital and Ramathibodi Chakri Naruebodindra Hospital with new onset smell loss who capable to perform nasal irrigation themselves. COVID-19, Anosmia, Hyposmia, Budesonide;COVID-19, Anosmia, Hyposmia, Budesonide
2
Medical Condition: covid 19 pneumonia. Multisystem inflammatory syndrome associated with COVID-19
2
Medical Condition: severe illness patients with COVID-19 COVID-19, acute respiratory distress syndrome (ARDS) , critical care, macrophage activation syndrome (MAS) , hemophagocytic lymphohitiocytosis (HLH) , etoposide, corticosteroid, HLH-94 protocol
2
Phase: Phase 3
2
Study Type: Observational
2